보고서 요약(국문)

개요
전 세계 뇌하수체 기능 저하증 치료 시장은 2022년 XX억 달러에 달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률로 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
뇌하수체 기능 저하증은 뇌하수체가 제대로 기능하지 않아 호르몬을 충분히 생성하지 못하는 질환입니다. 뇌하수체 기능 저하증은 뇌하수체에 직접적인 영향을 미치거나 시상하부의 변화를 통해 간접적으로 영향을 미칠 수 있습니다.
뇌하수체에서 분비되는 호르몬에는 항이뇨 호르몬, 성장 호르몬, 난포 자극 호르몬, 옥시토신 등이 있습니다. 호르몬 부족은 해당 호르몬이 조절하는 기관이나 샘의 기능 상실로 이어집니다. 예를 들어, 갑상선 자극 호르몬(TSH) 부족은 갑상선 기능 상실을 초래합니다.

시장 동향
뇌하수체 종양 발생 건수 증가
뇌하수체 기능 저하증을 유발할 수 있는 뇌하수체 종양의 유병률 증가는 시장 성장의 주요 동인입니다. 뇌하수체 종양은 뇌하수체에 발생하는 비정상적인 종양입니다. 대부분의 뇌하수체 종양은 양성이며 수술로 제거하거나 약물 또는 방사선 치료로 관리할 수 있습니다.
예를 들어, 존스 홉킨스 의과대학에 따르면 약 10명 중 1명꼴로 평생 동안 뇌하수체 선종이 발생합니다. 2023년 미국에서는 약 13,900건의 뇌하수체 종양이 진단되었으며, 이는 전체 원발성 뇌종양의 약 17%를 차지합니다.
또한, 미국 암 협회 보고서에 따르면 미국에서는 매년 10,000건 이상의 뇌하수체 종양이 진단됩니다. 이러한 종양의 거의 대부분은 양성이며, 악성 종양은 소수에 불과합니다.

또한, 뇌하수체 기능 저하증 치료제 임상 시험 증가 및 성장 호르몬 개발과 같은 주요 성장 동력이 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.
치료 약물 관련 부작용
치료 약물은 졸음, 현기증, 메스꺼움, 구토, 설사 또는 변비, 두통, 방향 감각 상실, 우울증과 같은 부작용을 유발할 수 있습니다. 또한, 성장 호르몬 결핍은 성장 장애 및 저신장을 유발할 수 있으며, 근육 약화, 피로, 체지방 변화로 이어질 수 있습니다.
세분화 분석
전 세계 뇌하수체 기능 저하증 치료 시장은 유형, 치료 방법, 최종 사용자 및 지역별로 세분화됩니다.
호르몬 대체 요법 부문은 시장 점유율의 약 56.8%를 차지했습니다.
호르몬 대체 요법 부문은 임상 시험 건수 증가로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 뇌하수체 기능 저하증 치료를 위한 임상 시험은 총 189건이 진행되었습니다.

예를 들어, clinicaltrial.gov에 따르면, 2023년 2월 8일 신경학 연구 센터는 노보 노디스크(Novo Nordisk A/S)와 협력하여 은퇴한 프로 미식축구 선수들을 대상으로 성장호르몬 대체 요법에 대한 임상 시험을 시작했습니다. 해당 질환에는 전뇌하수체 분비 저하 증후군 및 뇌하수체 기능 저하증이 포함됩니다. 연구 완료 예정일은 2025년 3월입니다.
또한, 2023년 12월 5일 노보 노디스크(Novo Nordisk A/S)는 성장호르몬 치료를 받는 소아 환자를 대상으로 주 1회 투여하는 소마파시탄(Somapacitan)과 매일 투여하는 노르디트로핀 플렉스프로(Norditropin FlexPro)의 효능 및 안전성을 비교하는 임상 시험을 시작했습니다. 연구 완료 예정일은 2024년 9월입니다. 따라서 위와 같은 요인들로 인해 해당 부문이 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
지역 분석
북미는 전 세계 뇌하수체 기능 저하증 치료 시장에서 상당한 비중을 차지할 것으로 예상됩니다.
전 세계 뇌하수체 기능 저하증 치료 시장은 북미, 유럽, 아시아 태평양, 남미, 중동 및 아프리카로 구분됩니다. 북미는 뇌하수체 기능 저하증 유병률 증가 및 의료비 지출 증가와 같은 요인으로 인해 상당한 시장 점유율을 유지해 왔으며, 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.
예를 들어, 미국 국립보건원(NIH)은 뇌하수체 기능 저하증을 미국 내 20만 명 미만의 환자에게 영향을 미치는 희귀 질환으로 분류하고 있습니다. 전 세계적으로 뇌하수체 기능 저하증의 발생률은 연간 10만 명당 4.2건, 유병률은 10만 명당 45.5건으로 추정됩니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 뇌하수체 기능 저하증 치료 시장에 상당한 영향을 미쳤습니다. 2020년 초 팬데믹 발생으로 인해 광범위한 봉쇄와 제한 조치가 시행되었고, 이는 전 세계적으로 정기적인 진단, 치료, 신약 출시 및 상담에 영향을 미쳤습니다. 팬데믹 발생으로 인해 많은 제약 회사나 의료기기 제조업체는 인력 부족에 직면했고, 봉쇄 조치로 인해 직원들이 업무에 복귀할 수 없었습니다. 따라서 위와 같은 요인들로 인해 뇌하수체 기능 저하증 치료 시장은 예측 기간 동안 다소 영향을 받을 것으로 예상됩니다.
시장 세분화
유형별
• 단일 뇌하수체 기능 저하증
• 다발성 뇌하수체 호르몬 결핍증
• 범뇌하수체 기능 저하증
치료법별
• 호르몬 대체 요법
o 히드로코르티손 (코르테프)
o 프레드니손 (라요스)
o 레보티록신 (레복실)
o 성장 호르몬
o 생식 호르몬
• 수술
• 방사선 치료
최종 사용자별
• 병원
• 외래 수술 센터
• 전문 클리닉
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 기업으로는 Pfizer Inc., Horizon 등이 있습니다. 주요 기업으로는 Therapeutics Plc., Viatris Inc., AbbVie Inc., Weefsel Pharma, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, Omicron Pharma Pvt Ltd., Strides Pharma Science Limited 등이 있습니다.
주요 개발 사항
• 2023년 6월, 미국 FDA는 화이자와 OPKO Health가 공동 개발한 주사형 호르몬 치료제인 Ngenla를 성장호르몬 결핍증을 앓는 소아 환자 치료제로 승인했습니다.
보고서 구매 이유

• 유형, 치료법, 최종 사용자 및 지역별 글로벌 뇌하수체 기능 저하증 치료 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악하기 위해
• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별하기 위해

• 모든 세그먼트를 포함한 글로벌 뇌하수체 기능 저하증 치료 시장의 다양한 데이터가 담긴 Excel 데이터 시트

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 뇌하수체 기능 저하증 치료 시장 보고서는 약 61개의 표, 69개의 그림, 그리고 185페이지 분량으로 구성됩니다.
2023년 주요 독자층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Hypopituitarism Treatment Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.
Hypopituitarism occurs when the pituitary gland is not active and does not make enough hormones. Hypopituitarism can directly affect the pituitary gland or can indirectly affect the gland through changes in the hypothalamus.
The hormones released by the pituitary gland include antidiuretic hormone, growth hormone, follicle-stimulating hormone, and oxytocin. The lack of a hormone leads to loss of function in the gland or organ the hormone controls. For example, lack of thyroid-stimulating hormone (TSH) leads to loss of normal function of the thyroid gland.
Market Dynamics
Increasing number of pituitary tumor cases
The increasing prevalence of pituitary tumors that can cause hypopituitarism acts as a significant driver for market growth. Pituitary tumors are unusual growths that develop in the pituitary gland. Most pituitary tumors are benign and can be treated by removing with surgery or can be controlled with medications or radiation therapy.
For instance, according to John Hopkins Medicine, around 1 in 10 people develop a pituitary adenoma in their lifetime. About 13,900 pituitary gland tumors were diagnosed in the United States in 2023 by making up about 17% of all primary brain tumors.
Additionally, according to the American Cancer Society Report, more than 10,000 pituitary tumors are diagnosed each year in the United States. Almost all of these tumors are benign and only a few pituitary tumors are cancerous.
Furthermore, significant growth drivers such as the rising clinical trials for hypopituitarism drugs, and the development of growth hormones are expected to drive the market in the forecast period.
Side effects associated with treatment medications
The treatment medications can cause sleepiness, vertigo, nausea, vomiting, diarrhea or constipation, headaches, disorientation, and depression as adverse effects. Additionally, growth hormone deficiency can cause growth problems and short stature and can lead to Muscle weakness, fatigue, and changes in body fat.
Segment Analysis
The global hypopituitarism treatment market is segmented based on type, treatment, end user, and region.
The hormone replacement therapy segment accounted for approximately 56.8% of the market share
The hormone replacement segment is expected to hold the largest market share over the period forecast due to the increasing number of clinical trials. A total number of 189 clinical trials were conducted for hypopituitarism treatment.
For instance, according to clinicaltrial.gov, on February 8, 2023, the Center for Neurological Studies in collaboration with Novo Nordisk A/S started a clinical trial on growth hormone replacement therapy for retired professional football players. The condition includes anterior pituitary hyposecretion syndrome and hypopituitarism. The expected study completion date is March 2025.
Additionally, on December 5, 2023, Novo Nordisk A/S started a clinical trial on the efficacy and safety of once-weekly (Somapacitan) treatment compared to daily growth hormone treatment (Norditropin FlexPro) in children with growth hormone treatment. The expected study completion date is September 2024. Hence, due to the above factors, the segment is expected to hold the largest market share.
Geographical Analysis
North America is expected to hold a significant position in the global hypopituitarism treatment market share
The global hypopituitarism treatment market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. North America has maintained a significant market proportion due to factors such as the rising prevalence of hypopituitarism, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
For instance, hypopituitarism is listed as a rare disorder by the National Institutes of Health affecting less than 200,000 individuals in the United States. Globally, hypopituitarism has an estimated incidence of 4.2 cases per 100,000 per year and an estimated prevalence of 45.5 cases per 100,000.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global hypopituitarism treatment market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatment, drug launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the hypopituitarism treatment market is expected to be moderately affected over the forecast period.
Market Segmentation
By Type
• Isolated pituitary deficiency
• Multiple pituitary hormone deficiency
• Panhypopituitarism
By Treatment
• Hormone Replacement Therapy
o Hydrocortisone (Cortef)
o Prednisone (Rayos)
o Levothyroxine (Levoxyl)
o Growth Hormones
o Fertility Hormones
• Surgery
• Radiation therapy
By End User
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Pfizer Inc., Horizon Therapeutics Plc., Viatris Inc., AbbVie Inc., Weefsel Pharma, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, Omicron Pharma Pvt Ltd., and Strides Pharma Science Limited among others.
Key Developments
• In June 2023, the U.S FDA approved Pfizer and OPKO Health’s injectable hormone therapy called Ngenla for the treatment of pediatric patients suffering from growth hormone deficiency.
Why Purchase the Report?
• To visualize the global hypopituitarism treatment market segmentation based on type, treatment, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global hypopituitarism treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global hypopituitarism treatment market report would provide approximately 61 tables, 69 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing number of pituitary tumor cases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side effects associated with treatment medications
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Isolated pituitary deficiency*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Multiple pituitary hormone deficiency
7.4. Panhypopituitarism
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Hormone Replacement Therapy*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Hydrocortisone (Cortef)
8.2.4. Prednisone (Rayos)
8.2.5. Levothyroxine (Levoxyl)
8.2.6. Growth Hormones
8.2.7. Fertility Hormones
8.3. Surgery
8.4. Radiation therapy
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Specialty Clinics
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Horizon Therapeutics Plc
12.3. Viatris Inc.
12.4. AbbVie Inc.
12.5. Weefsel Pharma
12.6. Teva Pharmaceutical Industries Ltd.
12.7. Fresenius SE & Co KGaA
12.8. Omicron Pharma Pvt Ltd
12.9. Strides Pharma Science Limited
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Pfizer Inc., 4.	Key Developments, Horizon Therapeutics Plc, Viatris Inc., AbbVie Inc., Weefsel Pharma, Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, Omicron Pharma Pvt Ltd, Strides Pharma Science Limited

표 목록 (Tables)

List of Tables

Table 1 Global Hypopituitarism Treatment Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Hypopituitarism Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Hypopituitarism Treatment Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Hypopituitarism Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Hypopituitarism Treatment Market Value, By Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Hypopituitarism Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 7 Global Hypopituitarism Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Hypopituitarism Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 9 Global Hypopituitarism Treatment Market Value, By End User, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Hypopituitarism Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 11 Global Hypopituitarism Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Hypopituitarism Treatment Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Hypopituitarism Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 14 North America Hypopituitarism Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 15 North America Hypopituitarism Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 16 North America Hypopituitarism Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Hypopituitarism Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 18 South America Hypopituitarism Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 19 South America Hypopituitarism Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 20 South America Hypopituitarism Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Hypopituitarism Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 22 Europe Hypopituitarism Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 23 Europe Hypopituitarism Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 24 Europe Hypopituitarism Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Hypopituitarism Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Hypopituitarism Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Hypopituitarism Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Hypopituitarism Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Hypopituitarism Treatment Market Value, By Type, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Hypopituitarism Treatment Market Value, By Treatment, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Hypopituitarism Treatment Market Value, By End User, 2022-2031 (US$ Million)

Table 32 Pfizer Inc: Overview

Table 33 Pfizer Inc: Product Portfolio

Table 34 Pfizer Inc: Key Developments

Table 35 Horizon Therapeutics Plc: Overview

Table 36 Horizon Therapeutics Plc: Product Portfolio

Table 37 Horizon Therapeutics Plc: Key Developments

Table 38 Viatris Inc.: Overview

Table 39 Viatris Inc.: Product Portfolio

Table 40 Viatris Inc.: Key Developments

Table 41 AbbVie Inc.: Overview

Table 42 AbbVie Inc.: Product Portfolio

Table 43 AbbVie Inc.: Key Developments

Table 44 Weefsel Pharma: Overview

Table 45 Weefsel Pharma: Product Portfolio

Table 46 Weefsel Pharma: Key Developments

Table 47 Teva Pharmaceutical Industries Ltd.: Overview

Table 48 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 49 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 50 Fresenius SE & Co KGaA: Overview

Table 51 Fresenius SE & Co KGaA: Product Portfolio

Table 52 Fresenius SE & Co KGaA: Key Developments

Table 53 Omicron Pharma Pvt Ltd: Overview

Table 54 Omicron Pharma Pvt Ltd: Product Portfolio

Table 55 Omicron Pharma Pvt Ltd: Key Developments

Table 56 Strides Pharma Science Limited: Overview

Table 57 Strides Pharma Science Limited: Product Portfolio

Table 58 Strides Pharma Science Limited: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 2 Global Hypopituitarism Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 3 Global Hypopituitarism Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 4 Global Hypopituitarism Treatment Market Share, By End User, 2023 & 2031 (%)

Figure 5 Global Hypopituitarism Treatment Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Hypopituitarism Treatment Market Y-o-Y Growth, By Type, 2023-2031 (%)

Figure 7 Isolated pituitary deficiency Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 8 Multiple pituitary hormone deficiency Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 9 Panhypopituitarism Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 10 Global Hypopituitarism Treatment Market Y-o-Y Growth, By Treatment, 2023-2031 (%)

Figure 11 Hormone Replacement Therapy Treatment in Global Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 12 Surgery Treatment in Global Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 13 Radiation therapy Treatment in Global Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 14 Global Hypopituitarism Treatment Market Y-o-Y Growth, By End User, 2023-2031 (%)

Figure 15 Hospitals End User in Global Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 16 Ambulatory Surgical Centers End User in Global Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 17 Specialty Clinics End User in Global Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 18 End User in Global Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 19 Global Hypopituitarism Treatment Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 20 North America Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 21 Asia-Pacific Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 22 Europe Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 23 South America Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 24 Middle East and Africa Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 25 North America Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 26 North America Hypopituitarism Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 27 North America Hypopituitarism Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 28 North America Hypopituitarism Treatment Market Share, By End User, 2023 & 2031 (%)

Figure 29 North America Hypopituitarism Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 30 South America Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 31 South America Hypopituitarism Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 32 South America Hypopituitarism Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 33 South America Hypopituitarism Treatment Market Share, By End User, 2023 & 2031 (%)

Figure 34 South America Hypopituitarism Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 35 Europe Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 36 Europe Hypopituitarism Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 37 Europe Hypopituitarism Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 38 Europe Hypopituitarism Treatment Market Share, By End User, 2023 & 2031 (%)

Figure 39 Europe Hypopituitarism Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 40 Asia-Pacific Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 41 Asia-Pacific Hypopituitarism Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 42 Asia-Pacific Hypopituitarism Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 43 Asia-Pacific Hypopituitarism Treatment Market Share, By End User, 2023 & 2031 (%)

Figure 44 Asia-Pacific Hypopituitarism Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 45 Middle East & Africa Hypopituitarism Treatment Market Value, 2022-2031 (US$ Million)

Figure 46 Middle East & Africa Hypopituitarism Treatment Market Share, By Type, 2023 & 2031 (%)

Figure 47 Middle East & Africa Hypopituitarism Treatment Market Share, By Treatment, 2023 & 2031 (%)

Figure 48 Middle East & Africa Hypopituitarism Treatment Market Share, By End User, 2023 & 2031 (%)

Figure 49 Pfizer Inc: Financials

Figure 50 Horizon Therapeutics Plc: Financials

Figure 51 Viatris Inc.: Financials

Figure 52 AbbVie Inc.: Financials

Figure 53 Weefsel Pharma: Financials

Figure 54 Teva Pharmaceutical Industries Ltd.: Financials

Figure 55 Fresenius SE & Co KGaA: Financials

Figure 56 Omicron Pharma Pvt Ltd: Financials

Figure 57 Strides Pharma Science Limited: Financials

세계 뇌하수체 기능 저하증 치료 시장 – 2023-2030

Global Hypopituitarism Treatment Market - 2023-2030